Patent: 9,795,627
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,795,627
Title: | Method for prevention of colectomy |
Abstract: | A method of treating chronic active ulcerative colitis in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, comprises administering to a patient in need thereof an effective exposure of an oligonucleotide comprising the sequence 5\'-GGAACAGTTCGTCCATGGC-3\' (SEQ ID NO.2), wherein at least one CG dinucleotide is unmethylated. The oligonucleotide is not administered with corticosteroids or glucocorticosteroids. |
Inventor(s): | Admyre; Charlotte (Vendelso, SE), Zargari; Arezou (Solna, SE), Von Stein; Oliver (Upplands Vasby, SE), Von Stein; Petra (Upplands Vasby, SE) |
Assignee: | INDEX PHARMACEUTICALS AB (Stockholm, SE) |
Application Number: | 15/264,709 |
Patent Claims: | see list of patent claims |
Details for Patent 9,795,627
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | See Plans and Pricing | 2031-11-25 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |